Vano Highlights Trials and Data in RCC

Yann-Alexandre Vano, MD, Georges-Pompidou European Hospital, Paris, France, discusses some of the exciting data being seen in the renal cell carcinoma (RCC) space.

In addition to the phase 2 BIONIKK trial (NCT02960906) which showed that treatment with nivolumab (Opdivo) in combination with ipilimumab (Yervoy) in metastatic RCC is effective, Vano highlights biomarker data from the ​​the phase 3 CheckMate 9ER trial (NCT03141177). In this randomized, open-label study, the combination of nivolumab and cabozantinib (Cabometyx) was evaluated and compared with treatment with sunitinib (Sutent) monotherapy in patients with advanced RCC.

Here, nivolumab plus cabozantinib showed a continued clinically meaningful improvement in long-term survival and in responses among those enrolled in the study.

Vano also discusses a trial showing the efficacy of different treatments in patients with brain metastases, each of which were discussed at the 2023 Genitourinary Cancers Symposium.

Transcription:

0:10 | We have some biomarker data from CheckMate-9ER and we have updates from CheckMate-9ER [trial] of cabozantinib and nivolumab vs sunitinib [Suntent], which confirms the efficacy of this combination, but again, we have plenty of combinations in the first-line and we do not know how to use it. The biomarker parts of this trial are quite negative. We have data on the triplet of cabozantinib, nivolumab, and ipilimumab. We already know that this triplet is positive on PFS, negative on overall survival for the moment, and we know also that in lower risk patients, the triplet is not superior to the doublet. It would be a problem for this combination in the near future for the approval of this combination if these results are confirmed.

1:08 | Then, another study is showing the efficacy of different treatments in case of brain metastases. We see that brain metastasis is associated with a very poor prognosis and we have no clear efficacy of any treatments right now.